Status:
UNKNOWN
Liquid Biopsy for ctDNA in Peritoneal Lavage and Blood in Pancreatic Cancer
Lead Sponsor:
Sonke Detlefsen
Collaborating Sponsors:
Martin-Luther-Universität Halle-Wittenberg
University Hospital Schleswig-Holstein
Conditions:
Pancreatic Cancer
Pancreatic Adenocarcinoma
Eligibility:
All Genders
20-100 years
Brief Summary
Pancreatic cancer (PC) is a deadly disease and surgical resection of the tumor is the only hope of cure. Approximately 20-25% of the PC patients are candidates for intended curative resection, but des...
Detailed Description
1. Introduction Approximately 1.000 new cases of pancreatic cancer (PC) are diagnosed each year in Denmark. Ductal adenocarcinoma is by far the most frequent histological subtype of cancer in the panc...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients diagnosed with pancreatic cancer (adenocarcinoma) on a pancreatic resection specimen Age \> 18 years
- Exclusion Criteria:
- Duodenal carcinoma, ampullary carcinoma, bile duct cancer
- Benign surgical diagnosis
- Pregnancy
Exclusion
Key Trial Info
Start Date :
August 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05400681
Start Date
August 1 2020
End Date
December 31 2024
Last Update
June 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Odense University Hospital
Odense, Denmark, 5000